Independent Pharma Business Intelligence November 2026
Decision Radar
FDA & Regulatory IntelligenceClinical CatalystsCapital & Stock MarketCMC & Manufacturing Risk

Witfire Elite: Pharma News, FDA Decisions and Biotech Intelligence

FDA decisions, clinical trials and pharma deals, read from the primary filings: complete response letters, trial registries and company disclosures.

OLN324 mechanism of action brief: two ribbons of 28 lines fall across 12 weeks, the gold OLN324 ribbon to 180 and the grey faricimab ribbon to 121, with three injection marks
Breaking Analysis · Clinical Catalysts

OLN324 Mechanism of Action: How J&J’s $2.2 Billion Eye Drug Works and What 164 Patients Showed vs Faricimab

Johnson & Johnson is paying $2.2 billion upfront for a retina drug whose two completed trials enrolled 188 patients. OLN324 blocks the same two targets as Roche's Vabysmo with a protein just over a quarter of its size. This brief explains how it works, what its one head-to-head trial showed, and what four phase 3 trials are built to measure.

Read the analysis →
01 / Intelligence

Latest Pharma Intelligence

Decision-useful coverage for executives, investors, regulators and scientists.

02 / Breaking Analysis

Consequences, not headlines

Original analysis connecting scientific evidence, regulatory decisions and market value.

Witfire Elite Pharma News
July 2026 · Vol. I, No. 2

Chokepoints & Catalysts

The monthly issue
Witfire Elite Magazine

Where science meets strategy and breaks.

Witfire Elite Review, July 2026 -The Weakest Layer: The Stabilizer Ceiling, Eplontersen's CARDIO-TTRansform Miss, Unicycive OLC CRL.

Read the digital issue →